Accessibility StatementSkip Navigation SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker testing to help deliver information to doctors and patients, today announced the appointment of Tiffany Inglis, MD, FACOG, as Chief Medical Officer. With extensive clinical leadership expertise, Dr. Inglis will lead Sera's clinical operations to establish the company as ...

Company Overview - Sera Prognostics Inc. is focused on improving maternal and neonatal health through innovative pregnancy biomarker information [3] - The company aims to provide early pregnancy information to enhance the health of mothers and newborns, thereby reducing healthcare delivery costs [3] - Sera Prognostics is headquartered in Salt Lake City, Utah [3] Financial Results Announcement - The company will report its second quarter fiscal year 2025 financial results on August 6, 2025, after market close [1] - A conference call and live webcast will be held at 5:00 p.m. Eastern Time to discuss operational highlights and financial results [1][2] - A press release detailing the financial results will be distributed before the call [1] PreTRM® Test - The PreTRM® Test is a blood-based biomarker test that predicts the risk of spontaneous preterm birth in asymptomatic singleton pregnancies [5] - It measures proteins in the blood that are highly predictive of preterm birth, allowing for early identification of at-risk women [5] - The test enables personalized clinical decisions based on individual risk during weeks 18 to 20 of pregnancy [5] Preterm Birth Context - Preterm birth, defined as birth before 37 weeks' gestation, is the leading cause of illness and death in newborns [4] - Over the last five years, more than 10% of infants in the U.S. have been born prematurely [4] - The annual healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion in 2016 [4]

Company Overview - Sera Prognostics is a leading health diagnostics company focused on improving the lives of women and babies through precision pregnancy care [3] - The company's mission is to provide early, pivotal pregnancy information to enhance maternal and newborn health, ultimately reducing healthcare delivery costs [3] - Sera has a robust pipeline of innovative diagnostic tests aimed at early prediction of preterm birth risk and other pregnancy complications [3] Leadership Appointment - Mr. Lee Anderson has been appointed to a leadership role at Sera Prognostics, bringing extensive experience in the biotechnology and diagnostics sector [1] - Anderson previously held significant positions at Genomic Health and Exact Sciences, where he led US Oncology Sales and Global Customer Service, achieving nine consecutive years of revenue growth [1][2] - His role at Biofidelity Inc. as Chief Commercial Officer further enhanced his commercial strategy expertise and market presence [2] PreTRM® Test - The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides early, accurate, and individualized risk predictions for spontaneous preterm birth in asymptomatic singleton pregnancies [5] - This test analyzes proteins in the blood that are highly predictive of preterm birth, allowing physicians to identify at-risk women between weeks 18 and 20 of pregnancy [5] - The PreTRM® Test enables more informed and personalized clinical decisions based on individual risk assessments [5] Preterm Birth Context - Preterm birth, defined as any birth before 37 weeks' gestation, is the leading cause of illness and death in newborns [4] - Over the last six years, more than one in ten infants in the United States has been born prematurely, leading to significant long-term medical complications [4] - The estimated annual healthcare costs for managing complications related to prematurity in the U.S. were approximately $25 billion in 2016 [4]

Company Overview - Sera Prognostics Inc. is focused on improving maternal and neonatal health through innovative pregnancy biomarker information [3] - The company aims to provide early pregnancy information to enhance the health of mothers and newborns, thereby reducing healthcare delivery costs [3] - Sera Prognostics is headquartered in Salt Lake City, Utah [3] Financial Results Announcement - The company will report its first quarter fiscal year 2025 financial results on May 7, 2025, after market close [1] - A conference call and live webcast will be held at 5:00 p.m. Eastern Time to discuss operational highlights and financial results [1][2] - A press release with financial results will be distributed before the call [1] PreTRM® Test - The PreTRM® Test is a blood-based biomarker test that predicts the risk of spontaneous preterm birth in asymptomatic singleton pregnancies [5] - It measures proteins in the blood that are highly predictive of preterm birth, allowing for early identification of at-risk women [5] - The test enables personalized clinical decisions based on individual risk during weeks 18 to 20 of pregnancy [5] Preterm Birth Context - Preterm birth is defined as any birth before 37 weeks' gestation and is a leading cause of illness and death in newborns [4] - Over the last five years, more than 10% of infants in the U.S. have been born prematurely [4] - The annual healthcare costs for managing complications of prematurity in the U.S. were estimated at approximately $25 billion in 2016 [4]